Cybin Inc. Common Stock (HELP)

FairStock Score: 10/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Cybin through the old lens: a business must eventually produce cash. This is a clinical-stage biotech developing HLP003, a deuterated psilocybin analog in Phase 3 for major depressive disorder, and HLP004, a deuterated DMT analog in Phase 2 for generalized anxiety disorder. The provided figures show no revenue growth figure and no Lynch category because only zero years of filed results are available; the rule wants three. Financial health is poor: trailing free cash flow is -$142.3M and FCF yield is -47.2%, ROE is -86.94%, ROCE is -44.38%, and Piotroski F-Score is 1/9. The Altman Z-Score of 8.74 is high, but with no debt ratio supplied and no earnings, I do not treat that as proof of business quality. Valuation gives me little comfort. At the 2026-10-13 close of $10.50, market cap is $301.4M, the FairStock P/B is 2.69, and the FairStock P/E is -2.53—meaning losses make the multiple meaningless. FairStock Score is 10/100, and beta is 0.54. The moat is unproven; value depends on clinical and regulatory outcomes, not current cash generation. I see a speculative pipeline story, not a Graham bargain. The price already discounts substantial hope, while the cash burn requires future financing and possible dilution. I would need a much wider margin of safety or evidence of commercial success before calling this a sound value investment.

In plain English: Cybin is a clinical-stage drug company trying to develop treatments for depression and anxiety using psychedelic-related compounds. It does not yet make money and is burning a lot of cash, so the business looks weak by current financial measures. At $10.50 a share, the price looks expensive compared with those losses and cash use.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer